home / stock / aezs:cc / aezs:cc news

AEZS:CC News and Press, Aeterna Zentaris Inc. From 06/14/23

Stock Information
Company Name: Aeterna Zentaris Inc.
Stock Symbol: AEZS:CC
Market: TSXC
Website: zentaris.com
Menu
AEZS:CC AEZS:CC Quote AEZS:CC Short AEZS:CC News AEZS:CC Articles AEZS:CC Message Board
Get AEZS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AEZS:CC - Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all ite...
AEZS:CC - Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...

AEZS:CC - Aeterna Zentaris Reports First Quarter 2023 Financial Results

– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerat e recruitment for DETECT trial A ctively seeking alternate development and commercializatio...

AEZS:CC - Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

U . S . sales of Macrile n ® for adult use to be temporarily discontinued as of May 23, 2023 , while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen &#x...
AEZS:CC - Pharmanovia to Market GHRYVELIN(TM) (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

Pharmanovia to acquire license to GHRYVELIN ™ from Aeter n a Zentaris’ existing licensee, Consilient Health , effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (N...

AEZS:CC - Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

Aeterna Zentaris focuse d on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen ™ in the U . S . and Canad a Company c ontinu es to build growing body of data ac...

AEZS:CC - JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...
AEZS:CC - Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday , January 19 th at 3 :00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical comp...

AEZS:CC - Aeterna Zentaris Reports Third Quarter 2022 Financial Results

– Company ended the quarter with $ 53.8 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc....

AEZS:CC - Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

– Company ended the quarter with $58.2 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq:...
Previous 10 Next 10